Clinical Trials

700 enrolled

Papillomavirus Infections

NCT04199689 2025-03-25

V503-049

6,033 enrolled

Papillomavirus Infections

NCT00733122 2025-03-03

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Phase 3 Withdrawn

Papillomavirus Infections

NCT05829629 2025-02-14

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

Phase 1 Recruiting

20 enrolled

Papillomavirus Infections

NCT04528407 2025-02-13

BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects

Phase 1/2 Not yet recruiting

25 enrolled

Papillomavirus Infections

NCT03610581 2025-02-04

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Phase 1/2 Terminated

9 enrolled 13 charts

Papillomavirus Infections

NCT06797986 2025-01-29

A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.

37 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT06776055 2025-01-15

Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women

Active not recruiting

5,372 enrolled

Phase 3 Not yet recruiting

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT06281119 2025-01-07

Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

450 enrolled

Papillomavirus Infections

NCT06454175 2025-01-06

A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years

Phase 1 Active not recruiting

72 enrolled

Condylomata Acuminata, Papillomavirus Infections

NCT05285826 2024-12-16

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

8,100 enrolled

Papillomavirus Infections

NCT03487549 2024-11-27

COVE-1

Phase 2 Completed

56 enrolled 29 charts

DNA Virus Infections, Skin Diseases, Skin Diseases, Infectious, Tumor Virus Infections, Virus Diseases, Warts, Skin Diseases, Viral, Papillomavirus Infections

NCT03981822 2024-11-27

CARE-1

Phase 2 Completed

105 enrolled 24 charts

Condylomata Acuminata, Sexually Transmitted Diseases, Skin Diseases, Skin Diseases, Infectious, Virus Diseases, Warts, Sexually Transmitted Diseases, Viral, Skin Diseases, Viral, Papillomavirus Infections

NCT02653118 2024-11-12

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Active not recruiting

4,453 enrolled

Phase 1/2 Not yet recruiting

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT06672653 2024-11-04

PREPAP

66 enrolled

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT04199078 2024-10-31

PALOMA2

Phase NA Completed

288 enrolled

Papillomavirus Infections

NCT04472377 2024-10-03

HPV Typing Between Self- and Physician-sampled

Phase NA Completed

1,210 enrolled 7 charts

Vaginal Discharge, Papillomavirus Infections

NCT06439433 2024-06-03

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Phase 2 Completed

119 enrolled

Papillomavirus Infections

NCT06399341 2024-05-03

PAPILOBSGR

524 enrolled

Papillomavirus Infections

NCT05679141 2024-04-26

Clinical Correlation Between Self-collected and Physician-collected HPV Screening Kits

344 enrolled

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT04895020 2024-04-17

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Phase 3 Recruiting

1,200 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05027776 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Phase 3 Recruiting

1,348 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT05371353 2024-04-17

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Recruiting

600 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT02634190 2024-02-28

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

10,000 enrolled

Papillomavirus Infections

NCT05916911 2024-02-07

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Phase 4 Unknown

120 enrolled

Squamous Intraepithelial Lesions, Papillomavirus Infections

NCT06207175 2024-01-23

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Phase 3 Unknown

1,260 enrolled

Papillomavirus Infections

NCT06199128 2024-01-10

Fix

533 enrolled

Papillomavirus Infections

NCT03912831 2023-12-26

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Phase 1 Terminated

8 enrolled 13 charts

Neoplasms, Papillomavirus Infections

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

1,200 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT06111911 2023-11-01

Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)

Phase NA Completed

900 enrolled

Papillomavirus Infections

NCT06041061 2023-09-18

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years